Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR17 | Q13304 | 1/20 | 0.41 |
| ▸ | IMPDH2 | P12268 | 8/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.37 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.37 |
| ▸ | CDK9 | P50750 | 1/20 | 0.36 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.36 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.36 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4568189 | 0.92 | KDM4E (0.39) | GPR17IMPDH2IMPDH1DYRK1ADYRK1B | |
| SCHEMBL4568546 | 0.87 | TUBB4A (0.44) | GPR17PTGS2DYRK1A | |
| SCHEMBL3702535 | 0.85 | TUBB4A (0.48) | GPR17 | |
| SCHEMBL4568219 | 0.84 | GPR17 (0.41) | GPR17PTGS2DYRK1A | |
| SCHEMBL4568543 | 0.84 | GPR17 (0.41) | GPR17PTGS2 | |
| SCHEMBL3704461 | 0.84 | GPR17 (0.44) | GPR17 | |
| SCHEMBL3709862 | 0.84 | KDM4E (0.52) | GPR17 | |
| SCHEMBL3701562 | 0.83 | GPR17 (0.40) | GPR17PTGS2DYRK1A | |
| SCHEMBL4568215 | 0.83 | PTGS2 (0.41) | GPR17PTGS2DYRK1A | |
| SCHEMBL3704285 | 0.82 | GPR17 (0.43) | GPR17PTGS2DYRK1ADYRK2DYRK1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120122931-A1 | INDOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2012-05-17 | — | — | US | disclosed |
| US-20120122931-A1 | INDOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122931-A1 | INDOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | PTGER1, CYSLTR1, LTB4R | GPR17 59/4885IMPDH2 3385/4885PTGS2 257/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.